Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Allogene Therapeutics, Inc.

ALLO · Nasdaq · CIK 0001737287 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

3 Form 4 transaction lines observed in the same window
2 sales · 1 option, withholding, award, gift or other lines

Last qualifying purchase2024-05-16 · Belldegrun Arie · $5.0M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Kazam Joshua ADirector
○
Yoshiyama AnnieSVP, Finance
▼
Douglas Earl MartinSVP, General Counsel
▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-05-16 · Belldegrun Arie.

Recent Form 4 activity

0Purchases
14Sales
2Other Form 4 lines
16SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER1 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-24.0%
3M
-28.0%
6M
-39.3%
12M
—

Volatility & liquidity

Volatility
84.7%
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-65.3%
Industry
Biotechnology

Market data

Price data up to: 2026-10-02 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
55,606,815
Previous report
59,600,117
Avg daily volume
6,181,659
Days to cover
9.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-05-16Belldegrun AriePurchase (P)Common Stock1,724,137USD 2.90USD 4,999,997SEC filing ↗
2024-01-30Parker Geoffrey M.Purchase (P)Common Stock190USD 3.60USD 684SEC filing ↗
2022-01-12Kazam Joshua APurchase (P)Common Stock15,000USD 12.60USD 189,000SEC filing ↗
2022-01-12Belldegrun AriePurchase (P)Common Stock155,039USD 12.60USD 1,953,491SEC filing ↗
2020-06-04Belldegrun AriePurchase (P)Common Stock146,382USD 47.00USD 6,879,954SEC filing ↗

Form 4 evidence

16 transaction lines in the latest 365-day window; 243 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-21Douglas Earl MartinSale (S)Common Stock29,697USD 2.12USD 62,958SEC filing ↗
2026-06-18Kazam Joshua AOption exercise / conversion (M)Common Stock47,700USD 0.00USD 0SEC filing ↗
2026-04-21Yoshiyama AnnieSale (S)Common Stock9,586USD 2.31USD 22,144SEC filing ↗
Show recent Form 4 evidence (16 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-21Douglas Earl MartinSale (S)Common Stock29,697USD 2.12USD 62,958SEC filing ↗
2026-06-18Kazam Joshua AOption exercise / conversion (M)Common Stock47,700USD 0.00USD 0SEC filing ↗
2026-04-21Yoshiyama AnnieSale (S)Common Stock9,586USD 2.31USD 22,144SEC filing ↗
2026-03-16Chang David DSale (S)Common Stock47,763USD 2.47USD 117,975SEC filing ↗
2026-03-16Beneski Benjamin MachinasSale (S)Common Stock4,835USD 2.47USD 11,942SEC filing ↗
2026-03-02Beneski Benjamin MachinasSale (S)Common Stock7,132USD 2.60USD 18,543SEC filing ↗
2026-02-02Yoshiyama AnnieSale (S)Common Stock4,167USD 1.72USD 7,167SEC filing ↗
2026-02-02Roberts ZacharySale (S)Common Stock35,700USD 1.77USD 63,189SEC filing ↗
2026-02-02Parker Geoffrey M.Sale (S)Common Stock24,001USD 1.76USD 42,242SEC filing ↗
2026-02-02Douglas Earl MartinSale (S)Common Stock22,900USD 1.76USD 40,304SEC filing ↗
2026-02-02Chang David DSale (S)Common Stock95,269USD 1.80USD 171,484SEC filing ↗
2026-02-02Beneski Benjamin MachinasSale (S)Common Stock7,549USD 1.73USD 13,060SEC filing ↗
2026-01-21Roberts ZacharySale (S)Common Stock26,269USD 1.56USD 40,980SEC filing ↗
2025-12-18Kazam Joshua AOption exercise / conversion (M)Common Stock47,700USD 0.00USD 0SEC filing ↗
2025-11-17Beneski Benjamin MachinasSale (S)Common Stock786USD 1.22USD 959SEC filing ↗
2025-10-21Parker Geoffrey M.Sale (S)Common Stock36,744USD 1.26USD 46,297SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerALLO
CIK0001737287
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history243 transaction lines from 2020-02-20 to 2026-08-21
6 P purchase lines · 124 S sale lines · 113 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.